Carl Dambkowski, serving as the Chief Medical Officer at Apogee Therapeutics, Inc. (NASDAQ: APGE), engaged in significant stock transactions on July 1, 2026, involving both the acquisition and sale of company shares. Mr. Dambkowski sold 5,500 shares of common stock for a total of $730,070. These shares were sold at a price of $132.74 per share. On the same day, he also acquired 4,125 shares of common stock through the exercise of stock options at $22.86 per share, a transaction valued at $94,297.
The sale of 5,500 shares was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Dambkowski adopted on September 22, 2025. The transaction comes as Apogee's stock trades near its 52-week high of $133.85, having delivered a remarkable 180% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, with shares trading at $132.92. InvestingPro offers 14 additional exclusive tips for APGE, providing deeper insights into the company's valuation and performance metrics. Following these transactions, Mr. Dambkowski directly holds 177,873 shares of Apogee Therapeutics common stock.
The exercised options were part of a larger grant that represents the right to purchase 175,345 shares of the company's common stock. These options vest in forty-eight equal monthly installments through December 18, 2027, subject to Mr. Dambkowski's continued service to the issuer. After this option exercise, Mr. Dambkowski retains options to purchase 114,790 additional shares of Apogee Therapeutics common stock.
In other recent news, Apogee Therapeutics has entered into a definitive agreement to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion. This acquisition follows significant developments in Apogee's lead program, zumilokibart, which is progressing into Phase III trials. The deal has prompted Mizuho and UBS to downgrade Apogee's stock to Neutral from Buy, with both firms adjusting their price targets to align with the acquisition price. Apogee Therapeutics Follow Analyze APGE Included in our AI-picked strategies Review strategies 132.92 ▲ +0.15 (+0.11%) Closed · 15:59:59 · USD 132.91 0.00 (0.00%) After Hours · 17:39:52 1D 1W 1M 6M 1Y 5Y Max Created with Highcharts 11.4.8 14:00 15:00 16:00 17:00 18:00 19:00 132.7 132.8 132.9 Analyze APGE
Additionally, Apogee Therapeutics has signed two agreements with Paragon Therapeutics for the discovery and development of antibodies targeting the interleukin 31 receptor (IL-31R). These agreements involve Paragon generating and characterizing antibody candidates, with Apogee compensating Paragon for its activities. In other developments, Apogee's shareholders elected directors and approved proposals at the company's 2026 Annual Meeting of Stockholders.
Furthermore, RBC Capital has raised its price target for Apogee to $97, maintaining a Sector Perform rating. This update follows a survey of dermatologists assessing the potential future use of zumilokibart in atopic dermatitis, revealing mixed expectations regarding its adoption.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is APGE undervalued or a trap? Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what APGE is really worth. Get instant clarity on APGE plus thousands of other stocks before the opportunity disappears. July Sale - 60% Off InvestingPro